Zacks Research Weighs in on Teladoc Health FY2024 Earnings

Teladoc Health, Inc. (NYSE:TDOC - Free Report) - Investment analysts at Zacks Research boosted their FY2024 EPS estimates for Teladoc Health in a report issued on Wednesday, November 13th. Zacks Research analyst R. Department now expects that the health services provider will earn ($1.15) per share for the year, up from their prior forecast of ($1.31). The consensus estimate for Teladoc Health's current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Teladoc Health's Q4 2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($1.05) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.89) EPS.

Several other research analysts also recently commented on TDOC. Deutsche Bank Aktiengesellschaft boosted their target price on Teladoc Health from $10.00 to $12.00 and gave the stock a "hold" rating in a research note on Friday, November 1st. The Goldman Sachs Group initiated coverage on shares of Teladoc Health in a research note on Friday. They issued a "buy" rating and a $14.00 price objective for the company. Royal Bank of Canada boosted their target price on shares of Teladoc Health from $9.00 to $10.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 9th. Evercore ISI increased their price target on Teladoc Health from $8.00 to $9.00 and gave the company an "in-line" rating in a research note on Tuesday, October 8th. Finally, Stifel Nicolaus cut their price objective on Teladoc Health from $16.00 to $9.00 and set a "hold" rating on the stock in a report on Thursday, August 1st. Fourteen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $12.08.

Teladoc Health Price Performance

Shares of Teladoc Health stock traded down $0.16 during trading on Monday, reaching $9.06. 4,705,528 shares of the company's stock were exchanged, compared to its average volume of 5,530,954. The firm's 50-day moving average price is $8.93 and its 200 day moving average price is $9.34. The company has a market cap of $1.56 billion, a P/E ratio of -1.57 and a beta of 0.90. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73. Teladoc Health has a 1-year low of $6.76 and a 1-year high of $22.54.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The business had revenue of $640.51 million for the quarter, compared to analysts' expectations of $630.50 million.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TDOC. Rubric Capital Management LP bought a new position in Teladoc Health in the 2nd quarter valued at about $45,267,000. Point72 Asset Management L.P. lifted its holdings in shares of Teladoc Health by 221.9% in the second quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider's stock valued at $51,865,000 after purchasing an additional 3,655,436 shares in the last quarter. Clearline Capital LP boosted its position in shares of Teladoc Health by 395.6% during the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider's stock valued at $42,682,000 after buying an additional 3,483,665 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in Teladoc Health during the third quarter worth $15,801,000. Finally, Maple Rock Capital Partners Inc. purchased a new stake in Teladoc Health in the 3rd quarter valued at $11,291,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Teladoc Health

In other news, CFO Mala Murthy sold 8,750 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total transaction of $62,650.00. Following the transaction, the chief financial officer now directly owns 85,767 shares of the company's stock, valued at $614,091.72. This represents a 9.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Willem Waters sold 4,218 shares of Teladoc Health stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total transaction of $30,200.88. Following the completion of the sale, the chief operating officer now directly owns 78,309 shares of the company's stock, valued at approximately $560,692.44. The trade was a 5.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,051 shares of company stock valued at $143,565. 0.95% of the stock is currently owned by company insiders.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.